Why the study?
The study was designed to evaluate the safety and efficacy of two different antithrombotic strategies, DAPT vs DOAC, following left atrial appendage closure with the LACbes occluder.
Does dual antiplatelet therapy (aspirin and ticagrelor) compared to rivaroxaban improve safety and efficacy after left atrial appendage closure in patients with non-valvular atrial fibrillation?
Does dual antiplatelet therapy (aspirin and ticagrelor) compared to rivaroxaban improve safety and efficacy after left atrial appendage closure in patients with non-valvular atrial fibrillation?
This trial protocol outlines a study to compare the safety and efficacy of dual antiplatelet therapy versus rivaroxaban following left atrial appendage closure with the LACbes occluder.
Answers are grounded in this paper and cite their sources.
Protocol tests DAPT versus rivaroxaban post-LACbes LAA closure; leaves open optimal regimen in nonvalvular AF.
INTRODUCTION: The purpose of this study is to evaluate the safety and efficacy of two different antithrombotic strategies, dual antiplatelet therapy (DAPT, aspirin and ticagrelor) and direct oral anticoagulant (DOAC, rivaroxaban), after left atrial appendage closure (LAAC) using the LACbes occluder. METHODS AND ANALYSIS: This study is a prospective, randomised, controlled and multicentre clinical trial that will compare the clinical efficacy of antiplatelet and anticoagulation therapy after LAAC with the LACbes occluder. It is planned to enrol 296 subjects with non-valvular atrial fibrillation (NVAF) who complete transcatheter closure of the left atrial appendage successfully. All subjects who pass the screening process and sign informed consent forms will be randomised in a 1:1 ratio to the DAPT group (aspirin 100 mg/day and ticagrelor 90 mg two times a day) or the DOAC group (rivaroxaban 15 mg/day). Baseline data within 24 hours after the operation and follow-up information at 3, 6 and 12 months will be recorded to investigate the difference in the incidence of device-related thrombosis, clinical thrombotic events, bleeding and other adverse events. ETHICS AND DISSEMINATION: Ethics approval has been obtained from the Ethics Committee of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Approval number SH9H-2022-T426-1). The protocol (Version: V1, 20230105) has also been submitted and approved by the institutional ethics committee at each participating centre. Results are expected in 2025 and will be disseminated through peer-reviewed journals and presentations at national and international conferences. TRIAL REGISTRATION NUMBER: ChiCTR2100046712. TRIAL REGISTRATION NAME: Different antithrombotic strategies after left atrial appendage closure with the LACbes occluder.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: